Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia–initiating CBFB::MYH11 oncofusion protein
Ryan B. Day, … , Christopher A. Miller, Timothy J. Ley
Ryan B. Day, … , Christopher A. Miller, Timothy J. Ley
Published December 7, 2023
Citation Information: J Clin Invest. 2024;134(4):e176311. https://doi.org/10.1172/JCI176311.
View: Text | PDF
Research Article Oncology

Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia–initiating CBFB::MYH11 oncofusion protein

  • Text
  • PDF
Abstract

Several canonical translocations produce oncofusion genes that can initiate acute myeloid leukemia (AML). Although each translocation is associated with unique features, the mechanisms responsible remain unclear. While proteins interacting with each oncofusion are known to be relevant for how they act, these interactions have not yet been systematically defined. To address this issue in an unbiased fashion, we fused a promiscuous biotin ligase (TurboID) in-frame with 3 favorable-risk AML oncofusion cDNAs (PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11) and identified their interacting proteins in primary murine hematopoietic cells. The PML::RARA- and RUNX1::RUNX1T1-TurboID fusion proteins labeled common and unique nuclear repressor complexes, implying their nuclear localization. However, CBFB::MYH11-TurboID–interacting proteins were largely cytoplasmic, probably because of an interaction of the MYH11 domain with several cytoplasmic myosin-related proteins. Using a variety of methods, we showed that the CBFB domain of CBFB::MYH11 sequesters RUNX1 in cytoplasmic aggregates; these findings were confirmed in primary human AML cells. Paradoxically, CBFB::MYH11 expression was associated with increased RUNX1/2 expression, suggesting the presence of a sensor for reduced functional RUNX1 protein, and a feedback loop that may attempt to compensate by increasing RUNX1/2 transcription. These findings may have broad implications for AML pathogenesis.

Authors

Ryan B. Day, Julia A. Hickman, Ziheng Xu, Casey D.S. Katerndahl, Francesca Ferraro, Sai Mukund Ramakrishnan, Petra Erdmann-Gilmore, Robert W. Sprung, Yiling Mi, R. Reid Townsend, Christopher A. Miller, Timothy J. Ley

×

Figure 2

PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11 have distinct protein interactomes in mouse hematopoietic cells.

Options: View larger image (or click on image) Download as PowerPoint
PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11 have distinct protein interac...
(A) Heatmap showing differentially interacting proteins (DIPs) (edgeR, FDR < 0.05, >2-fold change) with increased detection in PML::RARA-TurboID fusion samples (n = 12) relative to TurboID-alone samples (n = 23); the same proteins detected with the other TurboID fusion samples are plotted “passively.” Data are shown as z-scored normalized spectral counts. (B) Volcano plot of proteins identified in A, with selected proteins labeled. (C) The percentage of proteins in selected nuclear complexes with detectable interactions with PML::RARA-TurboID fusion, relative to TurboID alone. (D) Heatmap showing DIPs with increased detection in RUNX1::RUNX1T1-TurboID fusion samples (n = 6) relative to TurboID-alone samples (n = 23). (E) Volcano plot of proteins identified in D, with selected proteins labeled. (F) The percentage of proteins in selected nuclear complexes with detectable interactions with RUNX1::RUNX1T1-TurboID fusion, relative to TurboID alone. (G) Heatmap showing DIPs with increased detection in CBFB::MYH11-TurboID fusion samples (n = 8), relative to TurboID-alone samples (n = 23). (H) Volcano plot of proteins identified in G, with selected proteins labeled. (I) The percentage of proteins in selected nuclear complexes with increased interaction with CBFB::MYH11-TurboID fusions, relative to TurboID alone.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts